期刊文献+

唑来膦酸对老年骨质疏松性骨折及骨关节炎患者骨代谢的影响 被引量:19

The effect of Zoledronic acid on bone metabolism in elderly people with osteoporotic fractures or osteoarthritis
原文传递
导出
摘要 目的了解老年骨质疏松性骨折及骨关节炎患者应用唑来膦酸抗骨质疏松治疗后自身骨代谢变化特点。方法回顾性分析2013年5月至2014年11月北京医院骨科接受唑来膦酸治疗的105例老年患者(骨质疏松性骨折患者54例,骨关节炎患者51例),其骨代谢生化标志物总I型前胶原氨基端肽(tP1NP)、NMID骨钙素(OCN)和I型胶原羧基端肽口特殊序列(p—CTX)在治疗前、治疗后1周及治疗后1年的水平,并于治疗前、治疗后1年采用双能X线骨密度仪(DXA)测定患者腰椎及髋部骨密度。结果骨折患者治疗后1周较治疗前tP1NP升高(P〈0.05),骨关节炎患者治疗后1周较治疗前无明显变化(P〉0.05);所有患者治疗后1年较治疗前tP1NP降低(P〈0.001);所有患者治疗后1周较治疗前OCN降低(P〈0.05)、口CTX降低(P〈0.001),治疗后1年较治疗前OCN、pCTX均降低(P〈0.001),且骨折患者p-CTX降低幅度更为明屉(P〈0.05);所有患者治疗后1年与治疗前相比,髋部骨密度无明显变化(P〉0.05),腰椎骨密度增高(P〈0.05)。结论唑来膦酸作为骨吸收抑制剂能够有效降低骨科老年患者骨代谢水平,对于骨折患者的骨吸收抑制作用尤为明显,并能增加患者腰椎骨密度。 Objective To analyze the effects of treatment with Zoledronic acid on the characteristics of hone metabolism in elderly people with osteoporotic fractures versus osteoarthritis. Methods The 105 patients treated with Zoledronic acid (54 osteoporotic fractures patients, 51 osteoarthritis patients) were retrospectively analyzed from May 2013 to November 2014. The serum levels of total procollagen type 1 amino-terminal propeptide (tP1NP), N-MID osteocalcin(OCN), and β-crossLaps(β-CTX) were measured by ECLIA in all patients before and 1 week and 1 year after the treatment. Bone mineral density (BMD) was measured by dual energy X-ray densitometer (DXA) before and 1 year after the treatment. Results One week after treatment, tPlNP level were increased in osteoporotic fractures patients (P〈 0.05), while it was unchanged in osteoarthritis patients, OCN and 13 CTX level in all patients were decreased, especially in osteoporotic fractures patients(all P〈0.05). One year after treatment, tP1NP,OCN and β-CTX level in all patients were decreased(all P〈0. 001), BMD in lumber were increased(P〈0.05)while BMD in hip didn't change significantly( P 〉 0.05 ). Conclusions The treatment of Zoledronic acid can decrease bone metabolism in elderly people of orthopaedics effeetively, especially in osteoporotic fractures patients through inhibiting bone resorption, and can improve BMD in lumber significantly.
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2015年第7期782-785,共4页 Chinese Journal of Geriatrics
关键词 膦酸类 骨质疏松性 骨折 骨关节炎 Phosphonic acid Osteoporosis Fractures, bone Osteoarthritis
  • 相关文献

参考文献12

  • 1Deeks ED, Perry CM. Zoledronic acid: a review of its use in the treatment of osteoporosis[J]. Drugs Aging,2008, 25:963-986.
  • 2Marchese M, Zarattini G, Pazzaglia UE. The possible introduction of anti-osteoporosis drugs as anintegrated treatment in total hip arthroplasty[J]. Aging Clinical and Experimental Research, 2011, 23 (2 SuppI):36-37.
  • 3Szulc P-, Delmas PD. Biochemical markers of bone turnover in men[J]. Calcified Tissue International, 2001, 69,229-234.
  • 4何威,杨力,蔡德鸿.骨形成与吸收过程中的代谢生化标记物[J].中国临床康复,2005,9(42):118-120. 被引量:15
  • 5YamasakiS, Masuhara K, Yamaguchi K, et al. Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty[J]. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA,2007, 18.. 1009- 1015.
  • 6Carulli C, Civinini R, Matassi F, et al. The use of anti-osteoporosis drugs in total knee arthroplasty[J]. Aging Clinical and Experimental Research, 2011, 23 (2 Suppl) :38-39.
  • 7Black DM, Delmas PD, Eastell R,et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].The New England Journal of Medicine, 2007, 356 : 1809-1822.
  • 8Lyles KW, Colon-Emetic CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture[J]. The New England Journal of Medicine, 2007, 357 : 1799-1809.
  • 9Friedl G, Radl R, Stihsen C, et al. The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial [J].The Journal of Bone and Joint Surgery American Volume,2009, 91~ 274-281.
  • 10石磊,薛庆云.骨代谢指标和骨密度在骨折后变化意义的评价[J].中国骨质疏松杂志,2009,15(5):377-381. 被引量:15

二级参考文献47

  • 1夏维波.骨转换生化标志物的检测及临床评价[J].医师进修杂志,2005,28(5):3-6. 被引量:11
  • 2何威,杨力,蔡德鸿.骨形成与吸收过程中的代谢生化标记物[J].中国临床康复,2005,9(42):118-120. 被引量:15
  • 3Szulc P, Delmas PD. Biochemical markers of bone turnover in men. Calcif Tissue International, 2001,69 : 229-234.
  • 4Epstein S. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc, 2005, 80(3):379-388.
  • 5Watts NB. Clinical utility of biochemical markers of bone remodeling. Clinical Chemistry, 1999, 45(8) : 1359-1368.
  • 6Ducy P, Desbois C, Boyce B, et al. Increased bone formation in osteocalcin-delicient mice. Nature,1996, 382(6590) :448-452.
  • 7Kleerekoper M. Biochemical markers of bone remodeling. Southern Society for Chnical Investigation, 1996, 312(6) : 270-277.
  • 8Nakasato YR, Janckila AJ, Halleen JM, et al. Clinical significance of immunoassays for type-5 tartrate-resistant acid phosphatase. Clin Chem, 1999, 45(12) :2150-2157.
  • 9Clowes JA. The role of bone turnover markers and risk factors in the assessment of osteoporosis and fracture risk. Clinical Endocrinology and Metabolism,2000, 14(2) :213-232.
  • 10Cumming SR, Bates D, Black DM. Clinical use of bone densitometry. The Journal of the American Medical Association, 2002, 288(15) : 1889-1897.

共引文献45

同被引文献155

引证文献19

二级引证文献172

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部